Image
Interactive Exchange

Incretin-Based Therapies for Type 2 Diabetes

Mechanism-Based Strategies to Achieve Patient-Centered Care

Meeting Slides

Suggested Readings

Standards of Medical Care in Diabetes-2012.

American Diabetes Association. Diabetes Care. 2012;35:S11-S63.

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action.

Campbell JE, Drucker DJ. Cell Metab. 2013;17:819-837.

AACE Comprehensive Diabetes Management Algorithm.

Garber AJ, Abrahamson MJ, Barzilay JI, et al. 2013. Endocr Pract. 2013;19:327-336.

Novel Therapies for the Management of Type 2 Diabetes Mellitus: Part 2. Addressing the Incretin Defect in the Clinical Setting in 2013.

Grunberger G. J Diabetes. 2013;5:241-253.

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes.

Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Diabetes Care. 2011;34 (suppl 2):S251-S257.

Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database.

Horton ES, Silberman C, Davis KL, Berria R. Diabetes Care. 2010;33:1759-1765.

Exenatide Once Weekly: Sustained Improvement in Glycemic Control and Cardiometabolic Measures Through 3 Years.

Macconell L, Pencek R, Li Y, Maggs D, Porter L. Diabetes Metab Syndr Obes. 2013;6:31-41. 

Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes.

Scheen AJ. Postgrad Med. 2013;125:7-20.

The Role of Co-morbidity in the Selection of Antidiabetic Pharmacotherapy in Type-2 Diabetes.

Tschope D, Hanefeld M, Meier JJ, et al. Cardiovasc Diabetol. 2013;12:62.

Blood Pressure-Lowering Effects of GLP-1 Receptor Agonists Exenatide and Liraglutide: a Meta-Analysis of Clinical Trials.

Wang B, Zhong J, Lin H, et al. Diabetes Obes Metab. 2013;15:737-749.

Interactive Presentation

Scientific Insights Into Incretin Signaling and Type 2 Diabetes

Jack L. Leahy, MD


Relevant Resources

Insulin Replacement Therapy for Type 2 Diabetes

Patient-Centered Management of Hyperglycemia in Primary Care

Improving Outcomes in Type 2 Diabetes

Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens

A Focus on Bipolar Depression

Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes

Clinical Issues in Type 2 Diabetes

Discussions and Debates Around GLP-1 Receptor Agonists

Clinical Issues in Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Improving Outcomes for Women with Type 2 Diabetes

Individualizing Evidence-Based Care

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Congenital and Acquired Lipodystrophy

Best Practices in Diagnosis and Management

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

Clinical Issues in Type 2 Diabetes

Consensus and Controversies Around Intensifying Noninsulin Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Clinical Updates in Type 2 Diabetes

An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Injecting New Ideas into Managing Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Multidimensional Issues in Type 2 Diabetes

Looking Beyond Hemoglobin A1c

GLP-1 Receptors Agonists in Type 2 Diabetes

Mechanistic Insights and Evolving Treatment Options

Pharmaceutical Economics and LDL-C Management

Implications for PCSK9 Inhibitors in Clinical Practice